Inflammation Research

, Volume 45, Issue 11, pp 531–540 | Cite as

Predictability of the clinical potency of NSAIDs from the preclinical pharmacodynamics in rats

  • A. Mukherjee
  • V. G. Hale
  • O. Borga
  • R. Stein
Original Research Papers


Objective and Design: Relevance of the preclinical pharmacodynamic, toxicity and pharmacokinetic parameters predicting the clinical potency of nonsteroidal antiinflammatory drugs (NSAIDs) was evaluated.

Material: Data for oral potencies of 24 NSAIDs in rats were collected from the literature and from New Drug Applications with respect to the following parameters: antiinflammatory, analgesic, antipyretic, acute ulcerogenic activities, acute toxicity, in vitro inhibition of prostaglandin synthesis, acid dissociation constant (pKa), octanolwater partition coefficient and elimination half-life.

Treatment: Data for most of the in vivo parameters in rats were collected following single dose administration with the exception of adjuvant arthritis. Single and daily clinical doses were considered. All of these NSAIDs have been approved for marketing although not all have been sold in the USA.

Methods: The preclinical data were compared to human dose (unit or daily doses) using single and multiple stepwise regression analyses.

Results: Analyses suggest that NSAIDs are effective in all models of preclinical tests for fever, pain and inflammation, however, carrageenin-induced rat paw edema model is clearly the best predictor of human dose. Rank order of preclinical models for predicting human dose is carrageenin >yeast induced fever>pressure induced pain=adjuvant arthritis in rats. The analysis suggested that the pain and adjuvant arthritis models in rats may also involve a prostaglandin independent mechanism. Of the two physicochemical factors tested, pKa contributed best to the carrageenin model towards predicting the clinical potency of NSAIDs. Mathematical relationships between human dose, carrageenin ED50 and pKa were established that may assist in the future clinical development of NSAIDs.

Conclusions: Carrageenin-induced paw edema model in rats is the most robust predictor of the clinical potency of NSAIDs. Acid dissociation constant (pKa) appears to be a secondary contributor to the potency of NSAIDs. The relevance of the data analyses for developing cyclooxygenase-2 (COX-2) selective NSAIDs is discussed.

Key words

Antiinflammatory Analgesic Antipyretic pKa Octanol-water partition coefficient NSAIDs Animal models Carrageenin ED50 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    Martin BK. Significant factors in the history of aspirin. In: Dixon AJ, Smith MJH, Martin BK, Wood PHN, editors. Salicylates. London: J&A Churchill, 1963:6–8.Google Scholar
  2. [2]
    Smith MJH. Salicylates and metabolism. J Pharm Pharmacol 1959;11:705–20.PubMedGoogle Scholar
  3. [3]
    Whitehouse MW. Properties of antiinflammatory drugs. In: Zucker E, editor. Progress in Drug Research. Vol 8. Basel: Birkhäuser, 1965:323–429.Google Scholar
  4. [4]
    Born GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962;194:927–9.PubMedGoogle Scholar
  5. [5]
    Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action of aspirin like drugs. Nature New Biol 1971;231:232–5.PubMedGoogle Scholar
  6. [6]
    Day RO, Graham GG, Williams KM, Champion GD, Jager JD. Clinical pharmacology of NSAIDs. In: Orme MC, editor. Anti-rheumatic drugs. New York: Pergamon Press, 1990:137–87.Google Scholar
  7. [7]
    Furst DE. Are there differences among nonsteroidal antiinflammatory drugs. Arthr Rheum 1994;37:1–9.Google Scholar
  8. [8]
    Brune K, Beck WS, Geisslinger G, Menzel-Soglowek S, Peskar BM. Aspirin-like drugs may block pain independently of prostaglandin synthesis inhibition. Experientia 1991;47:257–61.CrossRefPubMedGoogle Scholar
  9. [9]
    Adams SS, McCullough KF, Nicholson JS. Some biological properties of flurbiprofen, an anti-inflammatory, analgesic and antipyretic agent. Drug Res 1975;25:1786–91.Google Scholar
  10. [10]
    Brogden RN, Heel RC, Speight TM, Avery GS. Fenbufen: A review of its pharmacological properties and therapeutic use in rheumatic diseases and acute pain. Drugs 1981;21:1–22.PubMedGoogle Scholar
  11. [11]
    Brooks RR, Bonk KR, Decker GE, Miller KE. Anti-inflammatory activity of orpanoxin administered orally and topically to rodents. Agents Actions 1985;16:369–76.CrossRefPubMedGoogle Scholar
  12. [12]
    Burns JJ, Yu TF, Dayton PG, Gutman AB, Brodie BB. Biochemical pharmacological considerations of phenylbutazone and its analogues. Ann NY Acad Sci 1960;86:253–62.PubMedGoogle Scholar
  13. [13]
    Capetola RJ, Shriver DA, Rosenthale ME. Suprofen, a new peripheral analgesic. J Pharmac Exp Ther 1980;214:16–23.Google Scholar
  14. [14]
    Capetola RJ, Tolman EL, Argentieri DC, Simon DM, Rosenthal ME. Suprofen. In: Lewis AJ, Furst DE, editors. Nonsteroidal anti-inflammatory drugs. New York: Marcel Dekker, 1987:509–30.Google Scholar
  15. [15]
    Carty TJ, Eskra JD, Lombardino JG, Hoffman WW. Piroxicam, a potent inhibitor of prostaglandin production in cell culture. Structure-activity study. Prostaglandins 1980;19:51–9.PubMedGoogle Scholar
  16. [16]
    Chipkin RE, Latranyi MB, Lorio LC, Barnett A. Determination of analgesic drug efficacies by modification of the Randall and Selitto Rat Yeast Paw test. J Pharmacol Meth 1983;10: 223–9.CrossRefGoogle Scholar
  17. [17]
    Davies RO. Review of the animal and clinical pharmacology of diflunisal. Pharmacotherapy 1983;3 Suppl:9S-22.PubMedGoogle Scholar
  18. [18]
    Demerson CA, Humber LG, Abraham NA, Schilling G, Martel RR, Pace-Asciak C. Resolution of etodolac and anti-inflammatory and prostaglandin synthetase inhibiting properties of the enantiomers. J Med Chem 1983;26:1778–80.CrossRefPubMedGoogle Scholar
  19. [19]
    Egg D. Effects of glycosaminoglycan-polysulfate and two nonsteroidal anti-inflammatory drugs on prostaglandin E2 synthesis in chinese hamster ovary cell cultures. Pharmacol Res Commun 1983;15:709–17.PubMedGoogle Scholar
  20. [20]
    Enthoven D, Coffey JW, Wyler-Plaut. Carprofen. In: Lewis AJ, Furst DE, editors. Nonsteroidal anti-inflammatory drugs. New York: Marcel Dekker, 1987:313–28.Google Scholar
  21. [21]
    Erikson N, Furst DE. Mechanisms of action of nonsteroidal anti-inflammatory drugs. Am Ass Clin Chem 1988;9:9–18.Google Scholar
  22. [22]
    Eve NO. Tiaprofenic acid. In: Lewis AJ, Furst DE, editors. Nonsteroidal anti-inflammatory drugs. New York: Marcel Dekker, 1987:531–46.Google Scholar
  23. [23]
    Ferrari RA, Ward SJ, Zobre CM, Van Liew DK, Perrone MH, Connell MJ, et al. Estimation of the in vivo effect of cyclooxygenase inhibitors on prostaglandin E2 levels in mouse brain. Eur J Pharmacol 1990;179:25–34.CrossRefPubMedGoogle Scholar
  24. [24]
    Goldenberg MM, Boise KL, Ilse AC, Evaluation of a new anti-inflammatory/analgesic compound F-776, 5-(4-chlorophenyl)-β-hydroxy-2-furanpropanoic acid. Arch Int Pharmacodyn 1980;243:331–51.PubMedGoogle Scholar
  25. [25]
    Goto J, Muramatsu M, Hosoda K, Otomo S, Aihara H. The inhibitory effect of oxaprozin, a new non-steroidal anti-inflammatory drug on platelet aggregation. Folia Pharmacol Jpn 1984:83:395–400.Google Scholar
  26. [26]
    Grindel JM, O'Neill PJ, Yorgey KA, Schwartz MH, McKown LA, Migdalof BH, et al. The metabolism of zomepirac sodium. I. Disposition in laboratory animals and man. Drug Metab Dispos Biol Fate Chem 1980;8:343–8.PubMedGoogle Scholar
  27. [27]
    Guissou P, Cuisinaud G, Legheand J, Sassard J. Chronopharmacokinetics of indomethacin in rats. Drug Res 1987;37: 1034–7.Google Scholar
  28. [28]
    Hatanaka T, Inuma M, Sugibayashi K, Morimoto Y. Prediction of skin permeability of drugs. I. Comparison with artificial membrane. Chem Pharm Bull 1990;38:3452–9.PubMedGoogle Scholar
  29. [29]
    Herzfeldt CD, Kummel R. Dissociation constants, solubilities and dissolution rates of some selected nonsteroidal anti-inflammatories. Drug Development and Industrial Pharmacy 1983;9:767–93.Google Scholar
  30. [30]
    Higuchi S, Osada Y, Shioiri Y, Nakaike S, Muramatsu M, Tanaka M, et al. Anti-inflammatory activity of a non-steroidal anti-inflammatory agent, oxaprozin, in experimental animal models. Folia Pharmacol Jpn 1984;83:383–94.Google Scholar
  31. [31]
    Krause W, Kuhne G, Schillinger E. Pharmacokinetics and biotransformation of methane sulphonanilides with anti-inflammatory activity in the rat and monkey-comparison with piroxicam. Xenobiotica 1983;13:265–72.PubMedGoogle Scholar
  32. [32]
    Kuriyama K, Hiyama Y, Aoyama Y, Ichikawa K, Okumura M, Masumoto S, et al. Pharmacological studies of a non-steroidal analgesic and antipyretic drug of LFP 83. Folia Pharmacol Jpn 1989;93:61–73.Google Scholar
  33. [33]
    La-Rotanda MI, Cappelo B, Grimaldi M, Silipo C, Vittoria A. Analysis of the correlation between hydrophilic-lipophilic series of nonsteroidal anti-inflammatory drugs. Farmaco Sci 1988;43:439–55.Google Scholar
  34. [34]
    Laneuville O, Breuer DK, Dewitt DL, Hla T, Funk CD, Smith WL. Differential inhibition of human prostaglandin endoperoxide H synthases-1 and-2 by nonsteroidal antiinflammatory drugs. J Pharmac Exp Ther 1994;271:927–34.Google Scholar
  35. [35]
    Levesque L, Gaudreault RC, Marceau F. The interaction of 3,5-pyrazolidienedione drugs with receptors for f-Met-Leu-Phe on human neutrophil leukocytes: a study of their structure-activity relationship. Can J Physiol Pharmacol 1991;69:419–25.PubMedGoogle Scholar
  36. [36]
    Liauw L, Moscaritola JD, Burcher J. Diclofenac. In: Lewis AJ, Furst DE, editors. Nonsteroidal anti-inflammatory drugs. New York: Marcel Dekker, 1987:329–47.Google Scholar
  37. [37]
    Lombardino JG. Medicinal chemistry of acidic nonsteroidal antiinflammatory drugs. In: Lombardino JG, editor. Nonsteroidal antiinflammatory drugs. New York: John Wiley, 1985:266–397.Google Scholar
  38. [38]
    Lombardino JG, Otterness IG, Wiseman EH. Acidic anti-inflammatory agents, pharmacological and clinical data. Drug Res 1975;25:1629–35.Google Scholar
  39. [39]
    Loscher W, Blazaki D. Effect of non-steroidal anti-inflammatory drugs on fertility of male rats. J Reprod Fertil 1986;76:65–73.PubMedGoogle Scholar
  40. [40]
    Majerus PW, Stanford N. Comparative effects of aspirin and diflunisal on prostaglandin synthetase from human platelets and sheep seminal vesicles. J Clin Pharmac 1977;4 Suppl:15S-8.Google Scholar
  41. [41]
    Mangan FR. Nabumetone. In: Lewis AJ, Furst DE, editors. Nonsteroidal anti-inflammatory drugs. New York: Marcel Dekker, 1987:439–72.Google Scholar
  42. [42]
    Marshall L, Dietrich S, Chang J. Anti-inflammatory drug effects on arachidonic acid metabolism in glycogen-elicited rat peritoneal cells as determined by a one-step chromatographic procedure. Ann NY Acad Sci 1988;524:442–4.Google Scholar
  43. [43]
    Martel RR, Klicius J. Comparison in rats of the anti-inflammatory and gastric irritant effects of etodolac with several clinically effective anti-inflammatory drugs. Agents Actions 1982;12:295–7.CrossRefPubMedGoogle Scholar
  44. [44]
    Menasse R, Hedwall PR, Kraetz J, Pericin C, Riesterer L, Sallmann A, et al. Pharmacological properties of diclofenac sodium and its metabolites. Scand J Rheumatol 1978;22 Suppl:5s-16.Google Scholar
  45. [45]
    Berkow R, editor. Merck Manual of diagnosis and therapy. Rahway, N.J. Merck Research Laboratories, 1992.Google Scholar
  46. [46]
    Muchowski JM, Unger SH, Ackrell J, Cooper GF, Cook J, Gallegra P, et al. Synthesis and antiinflammatory and analgesic activity of 5-Aroyl-1,2-dihydro-3H-pyrrolo[1,2-a′]pyrole-1-carboxylic acids and related compounds. J Med Chem 1985; 28:1037–49.CrossRefPubMedGoogle Scholar
  47. [47]
    Nagatomi H, Ando K. Studies on the anti-inflammatory activity and ulcerogenic adverse effect of thiazole derivatives, especially 2-amino-thiazoleacetic acid derivatives. Drug Res 1984;43:599–603.Google Scholar
  48. [48]
    Otterness IG, Gans DJ. Nonsteroidal anti-inflammatory drugs: an analysis of the relationship between laboratory animal and clinical doses. J Pharm Sci 1988;77:790–5.PubMedGoogle Scholar
  49. [49]
    Palmer DG, Highton J, Mackinnon, Myers DB. Non-steroidal anti-inflammatory drugs in combination. Experimental observations. Clin Exp Rheum 1985;3:111–5.Google Scholar
  50. [50]
    Pong SF, Demuth SM, Kinney CM, Deegan P. Prediction of human analgesic dosages of nonsteroidal anti-inflammatory drugs from analgesic ED50 values in mice. Arch Int Pharmacodyn 1985;273:212–20.PubMedGoogle Scholar
  51. [51]
    Rainsford KD, editor. Salicylates. In: Anti-inflammatory and anti-rheumatic drugs. Florida: CRC Press, 1985:112.Google Scholar
  52. [52]
    Randall LO, Baruth H. Analgesic and anti-inflammatory activity of 6-chloro-alpha-methyl-carbazole-2-acetic acid. Arch Int Pharmacodyn 1976;220:94–114.PubMedGoogle Scholar
  53. [53]
    Rechenberg HK. Phenylbutazone. London: Edward and Arnold, 1962:11–62.Google Scholar
  54. [54]
    Risdall PC, Adams SS, Crampton EL, Marchant B. The disposition and metabolism of flurbiprofen in several species including man. Xenobiotica 1978;8:691–704.PubMedGoogle Scholar
  55. [55]
    Roszkowski AP, Rooks WH II, Tomolonis AJ, Miller LM. Anti-inflammatory properties of d-2-(6′-methoxy-2′ naphthyl)-propionic acid (naproxen). J Pharmac Exp Ther 1971;179:114–23.Google Scholar
  56. [56]
    Ruelius HW. Extrapolation from animals to man: Predictions, pitfalls and perspectives. Xenobiotica 1987;17:255–65.PubMedGoogle Scholar
  57. [57]
    Said SA, Foda AM. Influence of cimetidine on the pharmacokinetics of piroxicam in rat and man. Drug Res 1989;39:790–2.Google Scholar
  58. [58]
    Sallmann A. The chemistry of diclofenac sodium. Rheumatol Rehabil 1979;18:4–10.Google Scholar
  59. [59]
    Sanda M, Jacob GB, Fliedner L, Kennedy J, Gotz M. Etodolac. In: Lewis AJ, Furst DE. editors. Nonsteroidal antiinflammatory drugs. New York: Marcel Dekker, 1987:349–70.Google Scholar
  60. [60]
    Satterwhite JH, Boudinot FD. Pharmacokinetics of ketoprofen in rats: effect of age and dose. Biopharm Drug Dis 1992;13:197–212.Google Scholar
  61. [61]
    Schiantarelli P, Cadel S. Piroxicam pharmacologic activity and gastrointestinal damage by oral and rectal route. Drug Res 1981;31:87–92.Google Scholar
  62. [62]
    Schuster T, Afeche P, Feldmann K. Phenylbutazone and oxyphenbutazone. In: Rainsford KD, editor. Antiinflammatory and antirheumatic drugs. Florida: CRC Press, 1985:161–74.Google Scholar
  63. [63]
    Shen TV. Chemical and pharmacological properties of diflunisal. Pharmacotherapy 1983;3 Suppl 2:3S-8.PubMedGoogle Scholar
  64. [64]
    Sloboda AE, Oronsky AL, Kerwar SS. Fenbufen. In: Lewis AJ, Furst DE, editors. Nonsteroidal anti-inflammatory drugs. New York: Marcel Dekker, 1987:371–92.Google Scholar
  65. [65]
    Sloboda AE, Tolman EL, Osterberg AC, Panagides J. The pharmacological properties of fenbufen. Drug Res 1980;30: 716–21.Google Scholar
  66. [66]
    Smith RJ, Lomen PL, Kaiser DG. Flurbiprofen. In: Lewis AJ, Furst DE, editors. Nonsteroidal anti-inflammatory drugs. New York: Marcel Dekker, 1987:393–418.Google Scholar
  67. [67]
    Tarayre JP, Lauressergues H. Advantages of a combination of proteolytic enzymes, flavonoids and ascorbic acid in comparison with non-steroid anti-inflammatory agents. Drug Res 1977;27:1144–9.Google Scholar
  68. [68]
    Varma DR. Influence of dietary protein on the anti-inflammatory and ulcerogenic effects and on the pharmacokinetics of phenylbutazone in rats. J Pharmac Exp Ther 1979;211:338–44.Google Scholar
  69. [69]
    Wax J, Winder CV, Tessman DK, Stephens MD. Comparative activities, tolerance and safety of nonsteroidal anti-inflammatory agents in rats. J Pharmac Exp Ther 1975;192: 172–8.Google Scholar
  70. [70]
    Wiseman EH, Chang YH, Lombardino JG. Piroxicam, a novel anti-inflammatory agent. Drug Res 1976;26:1300–3.Google Scholar
  71. [71]
    Plakogiannis FM, McCauley JA. Sulindac. In: Florey K, editor. Analytical profiles of substances. New York: Academic Press, 1984:584.Google Scholar
  72. [72]
    Mihalic M, Hofman H, Kuftinec J, Krile B, Caplar V, Kajfez F, et al. Piroxicam. In: Florey K, editor. Analytical profiles of substances. New York: Academic Press, 1986;15:524.Google Scholar
  73. [73]
    Winter CA, Risely EA, Nuss CW. Carrageenin induced edema in hind paw of the rat as an assay for antiinflammatory drugs. Proc Soc Exp Biol Med 1962;111:544–7.PubMedGoogle Scholar
  74. [74]
    Newbould BB. Chemotherapy of arthritis induced in rats by mycobacterial adjuvant. Br J Pharmacol 1963;21:127–36.Google Scholar
  75. [75]
    Randall LO, Selitto JJ. A method for measurement of analgesic activity of inflamed tissue. Arch Int Pharmacodyn 1957;111:409–19.PubMedGoogle Scholar
  76. [76]
    Winder CV, Wax J, Serrano B, Scotti L, Stackhouse SP, Wheelock RH. Pharmacological studies of 1,2-dimethyl-3-phenyl-3-propionoxy pyrolidine, CI-427, an analgesic agent. J Pharmac Exp Ther 1961;133:117–28.Google Scholar
  77. [77]
    Dodge PW, Brodie DA, Young PR, Krause RA, Tekeli S. Presentation of antiinflammatory drug induced gastric lesions in rats by Abbott-29590. Am J Dig Dis 1974;19:449–57.CrossRefPubMedGoogle Scholar
  78. [78]
    Litchfield JT, Wilcoxon F. A simplified method of evaluating dose-effect experiments. J Pharmac Exp Ther 1949;96:99–113.Google Scholar
  79. [79]
    Otterness IG, Wiseman EH, Gans DJ. A comparison of the carrageenin edema test and ultraviolet light induced erythema test as predictors of the clinical dose in rheumatoid arthritis. Agents Actions 1979;9:177–83.PubMedGoogle Scholar
  80. [80]
    Furst DE, Paulus HE. Aspirin and other NSAIDs. In: McCarty DJ, Koopman WJ, editors. Arthritis and allied conditions. Vol 1. Philadelphia: Lea and Febiger, 1993: 567–602.Google Scholar
  81. [81]
    Cricket Software, Malvern PA, Cricket Graph v 1.3 for Macintosh, 1988.Google Scholar
  82. [82]
    Cox DR, Snell EJ, editors. Applied Statistics. New York, London: Chapman and Hall, 1982;20–42.Google Scholar
  83. [83]
    JMP Statistics and Graphics Guide. Version 3.1, SAS Institute, Cary, NC.Google Scholar
  84. [84]
    Johnson AG, Siedmann P, Day RO. NSAID-related adverse drug interactions with clinical relevance. Int J Clin PHarm Ther 1994;32:509–32.Google Scholar
  85. [85]
    Katz LM, Love PY. NSAIDs and the liver. In: Famaey JP, Paulus HE, editors. Therapeutic applications of NSAIDs. New York: Marcel Dekker, 1992:247–63.Google Scholar
  86. [86]
    Brooks PM, Day RO. Nonsteroidal antiinflammatory drugs, differences and similarities. New Engl J Med 1991;324:1716–25.PubMedGoogle Scholar
  87. [87]
    Brune K, Graf P, Glatt M. Inhibition of prostaglandin synthesis in vivo by nonsteroid anti-inflammatory drugs. Evidence for the importance of pharmacokinetics. Agents Actions 1976; 6:159–64.CrossRefPubMedGoogle Scholar
  88. [88]
    Futaki N, Takahashi S, Yokoyama N, Arai I, Higuchi S, Otomo S. NS-398, a new antiinflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins 1994;47:55–9.CrossRefPubMedGoogle Scholar
  89. [89]
    Chan CC, Boyce S, Brideau C, Ford-Hutchinson AW, Gordon R, Guay D, et al. Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: A novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J Pharmac Exp Ther 1995;274:1531–7.Google Scholar

Copyright information

© Birkhäuser Verlag 1996

Authors and Affiliations

  • A. Mukherjee
    • 1
  • V. G. Hale
    • 2
  • O. Borga
    • 2
  • R. Stein
    • 1
  1. 1.Division of Anti-inflammatoryAnalgesic and Ophthalmologic Drug ProductsRockvilleUSA
  2. 2.Office of Clinical Pharmacology and BiopharmaceuticsCenter for Drug Evaluation and Research, Food and Drug Administration (FDA)RockvilleUSA

Personalised recommendations